Pegylated synthetic human c-peptide

Summary

Pegylated synthetic human C-peptide is an investigational, long-acting form of human C-peptide produced by attaching polyethylene glycol (PEG) moieties to the 31-amino-acid C-peptide sequence. C-peptide, historically considered a byproduct of insulin biosynthesis, has demonstrated biological activity in correcting microvascular and neurological complications associated with type 1 diabetes. PEGylation improves pharmacokinetic properties, extending half-life and reducing dosing frequency. It is under preclinical and early clinical investigation primarily for diabetic complications including nephropathy, neuropathy, and retinopathy.

Mechanism of Action

Mimics endogenous C-peptide, which binds to cell surface receptors (proposed GPCRs) and activates intracellular signaling pathways including Na+/K+-ATPase stimulation, eNOS activation, and MAPK/ERK pathways; PEGylation extends plasma half-life and reduces immunogenicity compared to native C-peptide

Routes of Administration

Goals & Uses

• Improved pharmacokinetics over native C-peptidePharmacokinetic OptimizationModerate
• Diabetic retinopathy preventionOphthalmological / Diabetic ComplicationLow
• Diabetic peripheral neuropathy improvementNeuroprotection / Nerve FunctionModerate
• Diabetic nephropathy attenuationRenal ProtectionModerate
• Microvascular function restorationVascular / Diabetic ComplicationModerate

Contraindications

• Hypersensitivity to C-peptide or PEG excipientsAllergic / ImmunologicalHigh
• Severe renal impairmentOrganModerateKidney function concerns
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Type 2 diabetes with endogenous C-peptide productionEndocrineModerate

Adverse Effects

• Anti-PEG antibody formationImmunologicalUncommon
• HypoglycemiaMetabolicRareAbnormally low blood glucose
• Injection site reactionsLocalCommon
• Renal PEG accumulationRenalRare
• Mild flu-like symptomsSystemicUncommon

Drug Interactions

• InsulinModerateMay increase risk of low blood sugar
• ACE inhibitors / ARBsLow
• Other PEGylated biologicsModerate

Population Constraints

• Pediatric populationAgeRelative
• Elderly patients (>75 years)AgeRelative
• Patients with prior severe PEG hypersensitivityImmunologicalAbsolute
• Type 1 diabetes mellitus (C-peptide deficient)Endocrine / Target PopulationAbsolute

Regulatory Status

• European UnionInvestigationalNot approved by EMA; early-phase research compound
• United StatesInvestigationalNo FDA approval; investigational use only under IND frameworks in clinical research settings
• United KingdomInvestigationalNot approved by MHRA; research use only

No approved therapeutic use in any major jurisdiction. Investigational compound in early-phase clinical research. Not approved by FDA, EMA, or MHRA. Some formulations studied under IND or equivalent regulatory frameworks.

Evidence & Sources

No sources recorded yet.